Skip to main content
. 2017 Jan 18;8(9):14736–14747. doi: 10.18632/oncotarget.14718

Figure 6. AMPKα1 silence sensitizes icaritin-induced anti-HT-29 tumor activity in vivo.

Figure 6

Nude mice bearing HT-29 tumors, expressing non-sense control shRNA (“Ctl shRNA”) or AMPKα1 shRNA (“a”), were administrated daily with ICT (10 mg/kg, oral gavage) for 21 consecutive days; Tumor volume (A) and mice body weight (C) were recorded every 10 days for a total of 40 days; Tumor daily growth was also calculated (B). Day-5 after initial ICT administration, HT-29 tumors of three mice of ICT treatment group were isolated, expression of listed proteins in fresh tumor lysates was tested, and results were quantified (D, three repeats). Data were expressed as mean ± SD. *p < 0.05 vs. “Ctl shRNA” only group. #p < 0.05 vs. “ICT” treatment of “Ctl shRNA” group.